Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according to potential clinical trial eligibility: 3-year outcomes from prospective cohort study. Tifcemalimab combined with ...
Chen et al. construct a comprehensive immune landscape of lymphatic malformations (LMs) atlas at single-cell resolution, uncovering pro-inflammatory responses and immune dysfunction characteristic.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results